NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
76282-0718-67 | 76282-0718 | LANREOTIDE ACETATE | LANREOTIDE ACETATE | 60.0 mg/.2mL | Hormonal Therapy | Somatostatin Analog | Subcutaneous | May 21, 2024 | In Use | ||
71288-0569-90 | 71288-0569 | Leuprolide Acetate | Leuprolide Acetate | Hormonal Therapy | GnRH Agonist | Subcutaneous | May 15, 2024 | In Use | |||
65219-0284-12 | 65219-0284 | PLERIXAFOR | Plerixafor | 24.0 mg/1.2mL | Ancillary Therapy | Immunostimulant | Stem Cell Mobilizer | Subcutaneous | Jun 22, 2023 | In Use | |
62935-0227-10 | 62935-0227 | Leuprolide acetate | Eligard | 22.5 mg/.375mL | Hormonal Therapy | GnRH Agonist | Subcutaneous | Nov 27, 2023 | In Use | ||
68083-0155-01 | 68083-0155 | Plerixafor | Plerixafor | 24.0 mg/1.2mL | Ancillary Therapy | Immunostimulant | Stem Cell Mobilizer | Subcutaneous | May 3, 2024 | In Use | |
57894-0450-01 | 57894-0450 | Teclistamab | TECVAYLI | 90.0 mg/mL | Immunotherapy | Monoclonal Antibody | BCMA, CD3 | Subcutaneous | Oct 25, 2022 | In Use | |
55513-0710-01 | 55513-0710 | Denosumab | Prolia | 60.0 mg/mL | Immunotherapy | Monoclonal Antibody | RANKL | Subcutaneous | Jun 5, 2010 | In Use | |
57894-0469-01 | 57894-0469 | Talquetamab | TALVEY | 3.0 mg/1.5mL | Immunotherapy | T Cell Receptor (TCR) | GPRC5D, CD3 | Subcutaneous | Aug 9, 2023 | In Use | |
51991-0797-98 | 51991-0797 | Azacitidine | Azacitidine | 100.0 mg/50mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Subcutaneous | Aug 7, 2017 | Jan 31, 2024 | No Longer Used |
50242-0108-01 | 50242-0108 | Rituximab and hyaluronidase | Rituxan Hycela | 2000.0 U/mL, 2000.0 U/mL, 120.0 mg/mL | Immunotherapy | Monoclonal Antibody | CD20 | Subcutaneous | Jun 22, 2017 | In Use | |
72893-0016-02 | 72893-0016 | Efbemalenograstim alfa-vuxw | RYZNEUTA | 20.0 mg/mL | Immunotherapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Subcutaneous | Nov 23, 2023 | In Use | |
00069-0291-01 | 00069-0291 | filgrastim-aafi | Nivestym | 300.0 ug/.5mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Subcutaneous | Sep 24, 2018 | In Use | |
00004-0357-30 | 00004-0357 | Peginterferon alfa-2a | Pegasys | 180.0 ug/.5mL | Immunotherapy | Cytokine | Interferon | Subcutaneous | Mar 29, 2011 | Jun 30, 2024 | No Longer Used |
72374-0102-10 | 72374-0102 | Filgrastim-txid | NYPOZI | 480.0 ug/480ug | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Subcutaneous | Dec 16, 2024 | In Use | |
00069-4494-02 | 00069-4494 | Elranatamab-bcmm | Elrexfio | 76.0 mg/1.9mL | Immunotherapy | Monoclonal Antibody | BCMA, CD3 | Subcutaneous | Aug 15, 2023 | In Use | |
72374-0101-01 | 72374-0101 | Filgrastim-txid | NYPOZI | 300.0 ug/300ug | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Subcutaneous | Dec 16, 2024 | In Use | |
72374-0101-10 | 72374-0101 | Filgrastim-txid | NYPOZI | 300.0 ug/300ug | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Subcutaneous | Dec 16, 2024 | In Use | |
72374-0102-01 | 72374-0102 | Filgrastim-txid | NYPOZI | 480.0 ug/480ug | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Subcutaneous | Dec 16, 2024 | In Use | |
00069-0291-10 | 00069-0291 | filgrastim-aafi | Nivestym | 300.0 ug/.5mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Subcutaneous | Sep 24, 2018 | In Use | |
55513-0730-01 | 55513-0730 | Denosumab | XGEVA | 120.0 mg/1.7mL | Immunotherapy | Monoclonal Antibody | RANKL | Subcutaneous | Nov 18, 2010 | In Use | |
50419-0392-01 | 50419-0392 | LAROTRECTINIB | VITRAKVI | 20.0 mg/mL | Chemotherapy | Tyrosine Kinase Inhibitor | TRK | OROPHARYNGEAL | Jul 26, 2019 | In Use | |
50419-0393-03 | 50419-0393 | LAROTRECTINIB | VITRAKVI | 20.0 mg/mL | Chemotherapy | Tyrosine Kinase Inhibitor | TRK | OROPHARYNGEAL | Dec 6, 2022 | In Use | |
67046-1029-03 | 67046-1029 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Nov 11, 2024 | In Use | |
67046-0346-06 | 67046-0346 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Nov 8, 2024 | In Use | |
31722-0413-14 | 31722-0413 | TEMOZOLOMIDE | TEMOZOLOMIDE | 100.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Aug 23, 2024 | In Use |
Found 11398 results — Export these results